Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
- In development advice (0)
Set out priority areas for quality improvement in health and social care.
- New quality standards in the last 6 months (0)
- Updated quality standards in the last 6 months (0)
- In development quality standards (0)
Guidance by programme
Review the evidence across broad health and social care topics.
Reviews the clinical and cost-effectiveness of new treatments.
Review new diagnostic technologies for adoption in the NHS.
Review clinical and cost-effectiveness of specialised treatments.
Reviews new medical devices for adoption in the NHS.
Advice by programme
Products being developed or updated
News on this topic
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
Putting guidance into practice
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 3 shared learning examples for this topic: